Technical Analysis for DMAC - DiaMedica Therapeutics Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 2.85 | -5.94% | -0.18 |
DMAC closed down 5.94 percent on Monday, March 18, 2024, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
Earnings due: Mar 26
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 20 DMA | Bearish | 0.00% | |
Fell Below 200 DMA | Bearish | 0.00% | |
Fell Below 50 DMA | Bearish | 0.00% | |
MACD Bearish Centerline Cross | Bearish | 0.00% | |
180 Bearish Setup | Bearish Swing Setup | 0.00% | |
BB Squeeze Ended | Range Expansion | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Crossed Above 20 DMA | Bullish | -5.94% | |
Crossed Above 200 DMA | Bullish | -5.94% | |
Crossed Above 50 DMA | Bullish | -5.94% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 11 hours ago |
200 DMA Resistance | about 11 hours ago |
50 DMA Resistance | about 11 hours ago |
Fell Below Previous Day's Low | about 11 hours ago |
Possible Inside Day | about 12 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/26/2024
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Kidney Disease Stroke Dementia Ischemia Kallikrein Pancreatitis Acute Pancreatitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Kidney Disease Stroke Dementia Ischemia Kallikrein Pancreatitis Acute Pancreatitis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.75 |
52 Week Low | 1.46 |
Average Volume | 39,259 |
200-Day Moving Average | 2.94 |
50-Day Moving Average | 2.93 |
20-Day Moving Average | 2.97 |
10-Day Moving Average | 2.98 |
Average True Range | 0.16 |
RSI (14) | 44.13 |
ADX | 22.79 |
+DI | 23.36 |
-DI | 14.92 |
Chandelier Exit (Long, 3 ATRs) | 2.80 |
Chandelier Exit (Short, 3 ATRs) | 3.26 |
Upper Bollinger Bands | 3.17 |
Lower Bollinger Band | 2.77 |
Percent B (%b) | 0.2 |
BandWidth | 13.32 |
MACD Line | 0.00 |
MACD Signal Line | 0.02 |
MACD Histogram | -0.0188 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.02 | ||||
Resistance 3 (R3) | 3.03 | 3.00 | 2.99 | ||
Resistance 2 (R2) | 3.00 | 2.95 | 2.99 | 2.98 | |
Resistance 1 (R1) | 2.92 | 2.93 | 2.91 | 2.91 | 2.97 |
Pivot Point | 2.89 | 2.89 | 2.88 | 2.88 | 2.89 |
Support 1 (S1) | 2.81 | 2.84 | 2.80 | 2.80 | 2.73 |
Support 2 (S2) | 2.78 | 2.82 | 2.77 | 2.72 | |
Support 3 (S3) | 2.70 | 2.78 | 2.71 | ||
Support 4 (S4) | 2.69 |